Lynparza approved in China for 1L BRCAm ovarian
05 December 2019 07:00 GMT Lynparza approved in China as a 1st-line maintenancetherapy in BRCA-mutated advanced ovarian cancer AstraZeneca and MSD's Lynparza reduced the risk of disease progressionor death by 70% in BRCAm advanced ovarian cancer after response to 1st-line platinum-based chemotherapy Only PARP inhibitor approved in this setting in China AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the companies have received marketing authorisation from China's National Medical Products